23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Cytokinetics, Incorporated › 2025-2026

Cytokinetics, Incorporated 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Cytokinetics, Incorporated’s Form 8-K, filed May 27, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 414Asset managers, any item
  • 3,536Fund votes
  • May 27, 2026Meeting date

Results at a glance

Meeting of May 27, 2026: 6 items on Cytokinetics, Incorporated’s Form 8-K, filed May 27, 2026: 3 approved · 3 passed (calculated).

Dissent

Significant dissent: 1 director (20.8% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Cytokinetics, Incorporated in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Cytokinetics, Incorporated

These tallies are Cytokinetics, Incorporated’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 27, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Cytokinetics, Incorporated — official shareholder meeting results, meeting held May 27, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Edward M. Kaye, M.D. 104,633,356---- 3,234,8628,257,512 97%Passed (calculated)—
Elect Director: Wendell Wierenga, Ph.D. 85,427,010---- 22,441,2088,257,512 79%Passed (calculated)—
Elect Director: Nancy J. Wysenski 104,820,911---- 3,047,3078,257,512 97%Passed (calculated)—
2. Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Employee Stock Purchase Plan by 1,000,000 shares of 107,254,415261,354352,449 --8,257,512 99.8%Approved—
3. Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026 115,468,025269,258388,447 --0 99.8%Approved—
4. Advisory Vote on Executive Compensation 104,005,5313,018,095844,592 --8,257,512 97%Approved—

Source: Cytokinetics, Incorporated, Form 8-K, filed with the SEC on May 27, 2026 — read the filing on EDGAR.

How asset managers voted at the Cytokinetics, Incorporated 2025-2026 meeting

414 asset managers disclosed a vote on at least one Cytokinetics, Incorporated item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Edward M. Kaye, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 104,633,356WITHHELD: 3,234,862
Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Edward M. Kaye, M.D.

Cytokinetics, Incorporated’s own tally for this item (“Elect Director: Edward M. Kaye, M.D.”): 104,633,356 for, 3,234,862 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 63,947,327 for, 1,637,297 withheld, 7 abstained, 119 not voted.

FOR
FOR: 63,947,327ABSTAIN: 7WITHHOLD: 1,637,297NOT VOTED: 119
Largest asset managers voting on “Election of Class I Directors for terms expiring in 2029: Edward M. Kaye, M.D.” at Cytokinetics, Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard16,283,0150 70For
T. Rowe Price10,923,8470 01,164,738Mixed
Fidelity11,423,2450 00For
BlackRock8,039,8160 00For
Capital Group2,351,8430 00For
State Street1,952,0010 00For
Jackson National1,888,3830 00For
Charles Schwab1,381,3750 00For
Federated Hermes698,2210 00For
Principal497,2740 048,873Mixed
MUTUAL FUND SERIES TRUST484,6440 00For
Voya472,5620 00For
JPMorgan469,9120 00For
PENN SERIES FUNDS INC408,4650 00For
Equitable205,8400 0199,733Mixed
John Hancock351,6490 014,740For
American Century339,5300 00For
MFS305,6980 00For
Goldman Sachs281,7310 00For
FRANKLIN STRATEGIC SERIES256,3830 00For
Columbia Threadneedle255,7130 00For
TIAA241,4420 00For
WILLIAM BLAIR FUNDS228,9900 00For
Janus Detroit Street Trust225,6400 00For
Empower220,1540 00For

Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).

Elect Director: Nancy J. Wysenski

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 104,820,911WITHHELD: 3,047,307
Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Nancy J. Wysenski

Cytokinetics, Incorporated’s own tally for this item (“Elect Director: Nancy J. Wysenski”): 104,820,911 for, 3,047,307 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 63,958,674 for, 1,625,951 withheld, 6 abstained, 119 not voted.

FOR
FOR: 63,958,674ABSTAIN: 6WITHHOLD: 1,625,951NOT VOTED: 119
Largest asset managers voting on “Election of Class I Directors for terms expiring in 2029: Nancy J. Wysenski” at Cytokinetics, Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard16,283,0160 60For
T. Rowe Price10,923,8470 01,164,738Mixed
Fidelity11,423,2450 00For
BlackRock8,039,8160 00For
Capital Group2,351,8430 00For
State Street1,952,0010 00For
Jackson National1,888,3830 00For
Charles Schwab1,381,3750 00For
Federated Hermes698,2210 00For
Principal497,2740 048,873Mixed
MUTUAL FUND SERIES TRUST484,6440 00For
Voya472,5620 00For
JPMorgan469,9120 00For
PENN SERIES FUNDS INC408,4650 00For
Equitable205,8400 0199,733Mixed
John Hancock351,6490 014,740For
American Century339,5300 00For
MFS305,6980 00For
Goldman Sachs281,7310 00For
FRANKLIN STRATEGIC SERIES256,3830 00For
Columbia Threadneedle255,7130 00For
TIAA241,4420 00For
WILLIAM BLAIR FUNDS228,9900 00For
Janus Detroit Street Trust225,6400 00For
Empower220,1540 00For

Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).

Elect Director: Wendell Wierenga, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD
FOR: 85,427,010WITHHELD: 22,441,208
Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: Election of Class I Directors for terms expiring in 2029: Wendell Wierenga, Ph.D.

Cytokinetics, Incorporated’s own tally for this item (“Elect Director: Wendell Wierenga, Ph.D.”): 85,427,010 for, 22,441,208 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 50,207,324 for, 15,377,264 withheld, 43 abstained, 119 not voted.

FORWITHHOLD
FOR: 50,207,324ABSTAIN: 43WITHHOLD: 15,377,264NOT VOTED: 119
Largest asset managers voting on “Election of Class I Directors for terms expiring in 2029: Wendell Wierenga, Ph.D.” at Cytokinetics, Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard16,276,5430 436,436For
T. Rowe Price00 012,088,585Withhold
Fidelity11,423,2450 00For
BlackRock8,039,8160 00For
Capital Group2,351,8430 00For
State Street1,951,9050 096For
Jackson National315,6060 01,572,777Mixed
Charles Schwab1,381,3750 00For
Federated Hermes698,2210 00For
Principal497,2740 048,873Mixed
MUTUAL FUND SERIES TRUST484,6440 00For
Voya472,5620 00For
JPMorgan469,9120 00For
PENN SERIES FUNDS INC26,1510 0382,314Mixed
Equitable205,8400 0199,733Mixed
John Hancock198,5430 0167,846Mixed
American Century339,5300 00For
MFS305,6980 00For
Goldman Sachs281,7310 00For
FRANKLIN STRATEGIC SERIES256,3830 00For
Columbia Threadneedle255,7130 00For
TIAA241,4420 00For
WILLIAM BLAIR FUNDS228,9900 00For
Janus Detroit Street Trust225,6400 00For
Empower74,1540 0146,000Mixed

Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).

Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the…

Official resultCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%
FOR: 107,254,415AGAINST: 261,354
Details: description as filed, official tally, votes by 116 asset managers

Description as filed by funds: To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance thereunder by 1,000,000 shares of common stock.

Cytokinetics, Incorporated’s own tally for this item (“2. Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Employee St”): 107,254,415 for, 261,354 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Approval of the Amendment and Restatement of the Amended and Restated 2015 Employee Stock Purchase Plan to increase the number of authorized shares reserved for issuance under the Amended and Restated 2015 Employee Stock Purchase Plan by 1,000,000 shares of common stock The stockholders…”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 116 asset managers below reported 65,793,645 for, 28,784 against, 1 abstained, 119 not voted.

FOR
FOR: 65,793,645AGAINST: 28,784ABSTAIN: 1NOT VOTED: 119
Largest asset managers voting on “To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee Stock Purchase Pl” at Cytokinetics, Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard16,283,0210 10For
T. Rowe Price12,088,5850 00For
Fidelity11,423,2450 00For
BlackRock8,039,8160 00For
Capital Group2,351,8430 00For
State Street1,952,0010 00For
Jackson National1,888,3830 00For
Charles Schwab1,381,3750 00For
Federated Hermes698,2210 00For
Principal546,1470 00For
MUTUAL FUND SERIES TRUST484,6440 00For
Voya472,5620 00For
JPMorgan469,9120 00For
PENN SERIES FUNDS INC408,4650 00For
Equitable405,5730 00For
John Hancock366,3890 00For
American Century339,5300 00For
MFS305,6980 00For
Goldman Sachs281,7310 00For
FRANKLIN STRATEGIC SERIES256,3830 00For
Columbia Threadneedle255,7130 00For
TIAA241,4420 00For
WILLIAM BLAIR FUNDS228,9900 00For
Janus Detroit Street Trust225,6400 00For
Empower220,1540 00For

Showing the 25 largest of 116 asset managers. All 116 are in the interactive database (link above).

Advisory Vote on Executive Compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 104,005,531AGAINST: 3,018,095

Prior year: 95.5% for (May 14, 2025 meeting) ▲ 1.7 pts

Details: description as filed, official tally, votes by 413 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement.

Cytokinetics, Incorporated’s own tally for this item (“4. Advisory Vote on Executive Compensation”): 104,005,531 for, 3,018,095 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4: Advisory Vote on Executive Compensation The stockholders approved, on an advisory basis, the compensation of the named executive officers, as disclosed in the Company's Proxy Statement for the 2026 Annual Meeting of Stockholders.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 108 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Cytokinetics, Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard16,283,0164 10For
T. Rowe Price12,088,5850 00For
Fidelity11,423,2450 00For
BlackRock8,039,8160 00For
Capital Group2,351,8430 00For
State Street1,952,0010 00For
Jackson National1,802,69085,693 00For
Charles Schwab1,381,3750 00For
Federated Hermes698,2210 00For
Principal546,1470 00For
MUTUAL FUND SERIES TRUST484,6440 00For
Voya472,5620 00For
JPMorgan469,9120 00For
PENN SERIES FUNDS INC408,4650 00For
Equitable405,5730 00For
John Hancock366,3890 00For
American Century339,5300 00For
MFS305,6980 00For
Goldman Sachs281,7310 00For
FRANKLIN STRATEGIC SERIES256,3830 00For
Columbia Threadneedle255,7130 00For
TIAA241,4420 00For
WILLIAM BLAIR FUNDS228,9900 00For
Janus Detroit Street Trust225,6400 00For
Empower220,1540 00For

Fund voting reports, all 108 managers: 65,136,666 for, 342,191 against, 28,785 abstained, 119 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 332 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Cytokinetics, Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
T. Rowe Price18,395,8550 00For
Fidelity9,986,5180 00For
Wellington6,706,5760 00For
State Street5,003,7370 00For
BlackRock4,014,9531,007 2130For
Polar Capital Holdings Plc3,087,8540 00For
GEODE CAPITAL MANAGEMENT, LLC2,795,7920 00For
Avoro Capital Advisors LLC1,746,2540 00For
Capital Group1,586,7340 00For
Charles Schwab1,397,1020 00For
Frazier Life Sciences Management, L.P.1,159,8790 00For
Northern Trust1,040,7770 00For
Vanguard1,004,1670 00For
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC855,6710 00For
PRINCIPAL GLOBAL INVESTORS786,6780 00For
Capital Research Global Investors770,9990 00For
BNP Paribas Asset Management Holding S.A.0714,344 00Against
MELLON INVESTMENTS Corp702,6460 00For
Federated Hermes698,831622 00For
RTW INVESTMENTS, LP696,5710 00For
PICTET ASSET MANAGEMENT SA682,8810 00For
Melqart Asset Management (UK) Ltd615,0070 00For
BROWN ADVISORY INC559,6650 00For
Voya537,0170 00For
Foresite Capital Management IV, LLC503,1750 00For

Institutional-manager reports, all 332 managers: 77,453,582 for, 2,273,009 against, 663,892 abstained, 1,954 not voted, 246,596 mixed. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%
FOR: 115,468,025AGAINST: 269,258

Prior year: 99.9% for (May 14, 2025 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 110 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.

Cytokinetics, Incorporated’s own tally for this item (“3. Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026”): 115,468,025 for, 269,258 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: Ratification of Selection of Ernst & Young LLP as Our Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2026 The stockholders ratified the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent reg…”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 110 asset managers below reported 65,555,751 for, 96 against, 28,785 abstained, 119 not voted.

FOR
FOR: 65,555,751AGAINST: 96ABSTAIN: 28,785NOT VOTED: 119
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm ” at Cytokinetics, Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard16,283,0210 10For
T. Rowe Price12,088,5850 00For
Fidelity11,423,2450 00For
BlackRock8,039,8160 00For
Capital Group2,351,8430 00For
State Street1,951,90596 00For
Jackson National1,888,3830 00For
Charles Schwab1,381,3750 00For
Federated Hermes698,2210 00For
Principal546,1470 00For
MUTUAL FUND SERIES TRUST484,6440 00For
Voya472,5620 00For
JPMorgan469,9120 00For
PENN SERIES FUNDS INC408,4650 00For
Equitable405,5730 00For
John Hancock366,3890 00For
American Century339,5300 00For
MFS305,6980 00For
Goldman Sachs281,7310 00For
FRANKLIN STRATEGIC SERIES256,3830 00For
Columbia Threadneedle255,7130 00For
TIAA241,4420 00For
WILLIAM BLAIR FUNDS228,9900 00For
Janus Detroit Street Trust225,6400 00For
Empower220,1540 00For

Showing the 25 largest of 110 asset managers. All 110 are in the interactive database (link above).

Largest Cytokinetics, Incorporated shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 124,432,565 shares outstanding at the time of that meeting.

Fund voting reports: top Cytokinetics, Incorporated shareholders by shares voted on “To approve the amendment and restatement of the Company's Amended and Restated 2015 Employee…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 13.09%
2T. Rowe Price 9.71%
3Fidelity 9.18%
4BlackRock 6.46%
5Capital Group 1.89%
6State Street 1.57%
7Jackson National 1.52%
8Charles Schwab 1.11%
9Federated Hermes 0.56%
10Principal 0.44%
Institutional-manager reports: top Cytokinetics, Incorporated shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#Asset manager % of shares outstanding
1T. Rowe Price 14.78%
2Fidelity 8.03%
3Wellington 5.39%
4State Street 4.02%
5BlackRock 3.23%
6Polar Capital Holdings Plc 2.48%
7GEODE CAPITAL MANAGEMENT, LLC 2.25%
8Avoro Capital Advisors LLC 1.40%
9Capital Group 1.28%
10Charles Schwab 1.12%

Reported Cytokinetics, Incorporated holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Cytokinetics, Incorporated holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock16,548,011 13.30%Form 13F, quarter ended March 31, 2026
Entities affiliated with BlackRock, Inc.15,252,905 12.26%Proxy statement (DEF 14A), table as of February 28, 2026
Entities affiliated with Fidelity Investments13,101,596 10.53%Proxy statement (DEF 14A), table as of February 28, 2026
Vanguard Group12,048,131 9.68%Form 13F, quarter ended March 31, 2026
FMR (Fidelity)10,723,140 8.62%Form 13F, quarter ended March 31, 2026
Wellington Management8,009,489 6.44%Form 13F, quarter ended March 31, 2026
Entities affiliated with Wellington Management Group LLP6,530,884 5.25%Proxy statement (DEF 14A), table as of February 28, 2026
State Street5,745,193 4.62%Form 13F, quarter ended March 31, 2026
Goldman Sachs2,455,758 1.97%Form 13F, quarter ended March 31, 2026
Robert I. Blum1,646,586 1.32%Proxy statement (DEF 14A), table as of February 28, 2026

Percentages above are of 124,432,565 shares outstanding, as reported by Cytokinetics, Incorporated on its Form 10-Q dated May 4, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Cytokinetics, Incorporated's shareholder meeting held May 27, 2026, in the 2025-2026 proxy season, 414 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 3,536 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Cytokinetics, Incorporated's filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Cytokinetics, Incorporated's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 27, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Cytokinetics, Incorporated’s 10-Q dated May 4, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Cytokinetics, Incorporated proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Cytokinetics (CYTK) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/cytokinetics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.